title: The tumor microenvironment in esophageal cancer.
abstract: Esophageal cancer is a deadly disease, ranking sixth among all cancers in mortality. Despite incremental advances in diagnostics and therapeutics, esophageal cancer still carries a poor prognosis, and thus, there remains a need to elucidate the molecular mechanisms underlying this disease. There is accumulating evidence that a comprehensive understanding of the molecular composition of esophageal cancer requires attention to not only tumor cells but also the tumor microenvironment (TME), which contains diverse cell populations, signaling factors and structural molecules that interact with tumor cells and support all stages of tumorigenesis. In esophageal cancer, environmental exposures can trigger chronic inflammation, which leads to constitutive activation of pro-inflammatory signaling pathways that promote survival and proliferation. Antitumor immunity is attenuated by cell populations such as myeloid-derived suppressor cells and regulatory T cells, as well as immune checkpoints like programmed death-1. Other immune cells such as tumor-associated macrophages can have other pro-tumorigenic functions, including the induction of angiogenesis and tumor cell invasion. Cancer-associated fibroblasts secrete growth factors and alter the extracellular matrix to create a tumor niche and enhance tumor cell migration and metastasis. Further study of how these TME components relate to the different stages of tumor progression in each esophageal cancer subtype will lead to development of novel and specific TME-targeting therapeutic strategies, which offer considerable potential especially in the setting of combination therapy.
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.|Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: E W
authors.initials: EW
authors.lastname: Lin
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.|Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: T A
authors.initials: TA
authors.lastname: Karakasheva
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.|Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: P D
authors.initials: PD
authors.lastname: Hicks
authors.affiliation: Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Bass
authors.affiliation: Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.|Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.|Department of Genetics, University of Pennsylvania, Philadelphia, PA, USA.
authors.forename: A K
authors.initials: AK
authors.lastname: Rustgi
mesh_terms: D017209:Apoptosis / Q000235:genetics / Q000276:immunology; D059447:Cell Cycle Checkpoints / Q000235:genetics / Q000276:immunology; D004938:Esophageal Neoplasms / Q000235:genetics* / Q000473:pathology; D006801:Humans; D007249:Inflammation / Q000235:genetics* / Q000276:immunology / Q000473:pathology; D009361:Neoplasm Invasiveness / Q000276:immunology; D009389:Neovascularization, Pathologic / Q000235:genetics* / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D059016:Tumor Microenvironment / Q000235:genetics*